Thu, Jul 24, 2014, 1:56 PM EDT - U.S. Markets close in 2 hrs 4 mins

Recent

% | $
Click the to save as a favorite.

Pharmacyclics Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • jgmtruth jgmtruth Jun 4, 2012 10:17 AM Flag

    Awfully quit here...

    Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
    Date/Time: Monday, June 4, 2012; 10:30 AM — 10:45 AM (CT)
    Location: E354a
    Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio.
    Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
    Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
    Location: S405
    Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study. Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas....Patience Is A Virtue..We will know soon enough..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Oops ..Most important.Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
      Date/Time: Monday, June 4, 2012; 10:15 AM — 10:30 AM (CT)
      Location: E354a
      Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: Interim results of a phase Ib/II study. Dr. John C. Byrd et al., The Ohio State University, Columbus, Ohio.
      This Abstract was selected to be presented at the "Best of ASCO Meetings."

    • Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
      Date/Time: Monday, June 4, 2012; 10:15 AM — 10:30 AM (CT)
      Location: E354a
      Abstract # 6507: The Bruton's tyrosine kinase inhibitor PCI-32765 in treatment-naive chronic lymphocytic leukemia patients: Interim results of a phase Ib/II study. Dr. John C. Byrd et al., The Ohio State University, Columbus, Ohio.
      This Abstract was selected to be presented at the "Best of ASCO Meetings."

      Oral Presentation at ASCO, Chicago, IL (June 1-5, 2012)
      Date/Time: Monday, June 4, 2012; 10:30 AM — 10:45 AM (CT)
      Location: E354a
      Abstract # 6508: A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio.

      Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
      Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
      Location: S405
      Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study. Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

 
PCYC
103.25-0.67(-0.64%)1:56 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.